{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    10,
    13,
    18,
    24,
    39,
    46,
    47,
    52,
    53
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Exclusion Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.3.3",
        "sectionTitle": "Exclusion criteria",
        "description": "Reference to exclusion criteria in the inclusion criteria section regarding medical devices"
      },
      {
        "id": "ref_2",
        "name": "Adjudication Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Administrative structure of the trial",
        "description": "Reference for details on the Data Monitoring Committee and adjudication"
      },
      {
        "id": "ref_3",
        "name": "Interim Analysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.4",
        "sectionTitle": "Statistical Methods/Interim Analysis",
        "description": "Reference for details on trial stopping criteria and interim analysis"
      },
      {
        "id": "ref_4",
        "name": "Drug Profile Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2",
        "sectionTitle": "Drug Profile",
        "description": "Reference to the drug profile and safety profile in the benefit-risk assessment"
      },
      {
        "id": "ref_5",
        "name": "Renal Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3.4.1",
        "sectionTitle": "Assessment of Safety",
        "description": "Reference for renal safety monitoring protocols"
      },
      {
        "id": "ref_6",
        "name": "Hepatic Assessment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.1.2",
        "sectionTitle": "Hepatic external adjudication",
        "description": "Reference for assessment of hepatic events"
      },
      {
        "id": "ref_7",
        "name": "NYHA Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "NYHA Functional Classification",
        "description": "Reference to Appendix 10.3 for NYHA classification severity"
      },
      {
        "id": "ref_8",
        "name": "Modified Rankin Scale Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Modified Rankin Scale",
        "description": "Reference to Appendix 10.4 for stroke outcome assessment"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The respective procedure for illiterate patients (if included) is described in the Appendix 10.1.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.2.1 Kansas City Cardiomyopathy Questionnaire",
        "pageNumber": 48
      },
      {
        "id": "annot_2",
        "text": "For Japan only: The following events will be handled as 'deemed serious for any other reason': AEs which possibly lead to disability will be reported as SAEs.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.3.7.1 Definitions of AEs",
        "pageNumber": 54
      },
      {
        "id": "annot_3",
        "text": "Cancers of new histology and exacerbations of existing cancer must be reported as a serious event regardless of the duration between discontinuation of the drug and the occurrence of the cancer.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.3.7.1 Definitions of AEs",
        "pageNumber": 54
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "4.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-11-20",
        "description": "Final Protocol (Revised Protocol (based on Global Amendment 03))",
        "amendmentNumber": "Global Amendment 03"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 3,
      "versionCount": 1
    }
  }
}